Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PPM1B | O75688 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2387688 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL5317413 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL2387693 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL11545787 | 1.00 | TSHR (0.55) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL5556039 | 0.97 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL12831369 | 0.91 | TSHR (0.49) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL12635439 | 0.91 | TSHR (0.49) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL29234725 | 0.91 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL1238213 | 0.91 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 | |
| SCHEMBL1806931 | 0.91 | TSHR (0.53) | TSHRPPM1BPTPN1PPP1CCALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4048671-B1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | AMGEN INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4684786-A2 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS KRAS G12C AND KRAS G12D INHIBITORS IN THE TREATMENT OF CANCER | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20240190862-A1 | EPOXYAMIDES AS KRAS G12C AND KRAS G12D INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-06-13 | — | — | US | disclosed |
| EP-2811999-B1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2021-10-27 | — | — | EP | disclosed |
| US-10647709-B2 | Cysteine protease inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-05-12 | — | — | US | disclosed |
| US-20170008884-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2017-01-12 | — | — | US | disclosed |
| US-9403843-B2 | Cysteine protease inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150045393-A1 | Novel Cysteine Protease Inhibitors and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-12 | — | — | US | disclosed |
| EP-2811999-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013116663-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-08-08 | — | — | WO | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | DAIAMED (US) | 2009-06-04 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501404-B2 | Substituted azetidinones | DAIMED (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| US-20060172952-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-08-03 | — | — | US | disclosed |
| US-7056947-B2 | For inhibiting (cysteine) proteases/caspases; for treatment of viral infections, stroke, neurodegenerative disease, and inflammatory diseases | GEORGIA TECH RESEARCH CORP. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20040048327-A1 | Aza-peptide epoxides | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-11 | — | — | US | disclosed |
| EP-0655447-A1 | Epoxysuccinic acid derivatives | Takeda Chemical Industries, Ltd. (JP) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | TSHR 414/4885PPM1B 4517/4885PTPN1 3065/4885 |
| US-20170008884-A1 | NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF | CAPNS1, CAPN9, CAPN1 | TSHR 4818/4885PPM1B 1879/4885PTPN1 2873/4885 |
| US-20150045393-A1 | Novel Cysteine Protease Inhibitors and Uses Thereof | CAPNS1, CAPN9, CAPN1 | TSHR 4818/4885PPM1B 1879/4885PTPN1 2873/4885 |
| US-20240190862-A1 | EPOXYAMIDES AS KRAS G12C AND KRAS G12D INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | TSHR 4494/4885PPM1B 2182/4885PTPN1 3117/4885 |
| US-20060172952-A1 | Aza-peptide epoxides | CAPN9, CAPNS1, IAPP | TSHR 4233/4885PPM1B 1371/4885PTPN1 3823/4885 |
| US-10647709-B2 | Cysteine protease inhibitors and uses thereof | CAPNS1, CAPN9, CAPN1 | TSHR 4771/4885PPM1B 1782/4885PTPN1 2433/4885 |
| US-20090143351-A1 | SUBSTITUTED AZETIDINONES | F2R, CPA3, CFD | TSHR 414/4885PPM1B 4517/4885PTPN1 3065/4885 |
| US-20040048327-A1 | Aza-peptide epoxides | ANPEP, ENPEP, TMPRSS15 | TSHR 4503/4885PPM1B 1421/4885PTPN1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.